FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2059663906> ?p ?o ?g. }

• W2059663906 endingPage "2622" @default.
• W2059663906 startingPage "2615" @default.
• W2059663906 abstract "Hepatic glucose overproduction is a major characteristic of type 2 diabetes. Because glucagon is a key regulator for glucose homeostasis, antagonizing the glucagon receptor (GCGR) is a possible therapeutic strategy for the treatment of diabetes mellitus. To study the effect of hepatic GCGR inhibition on the regulation of lipid metabolism, we generated siRNA-mediated GCGR knockdown (si-GCGR) in the db/db mouse. The hepatic knockdown of GCGR markedly reduced plasma glucose levels; however, total plasma cholesterol was increased. The detailed lipid analysis showed an increase in the LDL fraction, and no change in VLDL HDL fractions. Further studies showed that the increase in LDL was the result of over-expression of hepatic lipogenic genes and elevated de novo lipid synthesis. Inhibition of hepatic glucagon signaling via siRNA-mediated GCGR knockdown had an effect on both glucose and lipid metabolism in db/db mice. Hepatic glucose overproduction is a major characteristic of type 2 diabetes. Because glucagon is a key regulator for glucose homeostasis, antagonizing the glucagon receptor (GCGR) is a possible therapeutic strategy for the treatment of diabetes mellitus. To study the effect of hepatic GCGR inhibition on the regulation of lipid metabolism, we generated siRNA-mediated GCGR knockdown (si-GCGR) in the db/db mouse. The hepatic knockdown of GCGR markedly reduced plasma glucose levels; however, total plasma cholesterol was increased. The detailed lipid analysis showed an increase in the LDL fraction, and no change in VLDL HDL fractions. Further studies showed that the increase in LDL was the result of over-expression of hepatic lipogenic genes and elevated de novo lipid synthesis. Inhibition of hepatic glucagon signaling via siRNA-mediated GCGR knockdown had an effect on both glucose and lipid metabolism in db/db mice. Glucagon is a counterregulatory hormone of insulin that has an important physiological role regulating glucose metabolism and preventing hypoglycemia in both animals and humans. The primary target organ of glucagon is liver. Hepatic glucagon receptor and glucagon interaction increases hepatic glucose production by activating glycogenolysis and gluconeogenesis, and abnormal glucagon signaling is associated with hyperglycemia in patients with type 2 diabetes (1D'Alessio D. The role of dysregulated glucagon secretion in type 2 diabetes.Diabetes Obes. Metab. 2011; 13: 126-132Crossref PubMed Scopus (177) Google Scholar). Several preclinical and clinical studies have demonstrated the utility of inhibiting glucagon signaling as one potential strategy for the treatment of type 2 diabetes. For example, pharmacologic or antisense oligonucleotide (ASO) interventions that suppress glucagon receptor signaling have been shown to reverse hyperglycemia in animal models (2Petersen K.F. Sullivan J.T. Effects of a novel glucagon receptor antagonist (Bay 27–9955) on glucagon-stimulated glucose production in humans.Diabetologia. 2001; 44: 2018-2024Crossref PubMed Scopus (195) Google Scholar, 3Qureshi S.A. Rios C.M. Xie D. Yang X. Tota L.M. Ding V.D. Li Z. Bansal A. Miller C. Cohen S.M. et al.A novel glucagon receptor antagonist inhibits glucagon-mediated biological effects.Diabetes. 2004; 53: 3267-3273Crossref PubMed Scopus (94) Google Scholar, 4Winzell M.S. Brand C.L. Wierup N. Sidelmann U.G. Sundler F. Nishimura E. Ahren B. Glucagon receptor antagonism improves islet function in mice with insulin resistance induced by a high-fat diet.Diabetologia. 2007; 50: 1453-1462Crossref PubMed Scopus (53) Google Scholar, 5Sloop K.W. Cao J.X. Siesky A.M. Zhang H.Y. Bodenmiller D.M. Cox A.L. Jacobs S.J. Moyers J.S. Owens R.A. Showalter A.D. et al.Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors.J. Clin. Invest. 2004; 113: 1571-1581Crossref PubMed Scopus (189) Google Scholar, 6Liang Y. Osborne M.C. Monia B.P. Bhanot S. Gaarde W.A. Reed C. She P. Jetton T.L. Demarest K.T. Reduction in glucagon receptor expression by an antisense oligonucleotide ameliorates diabetic syndrome in db/db mice.Diabetes. 2004; 53: 410-417Crossref PubMed Scopus (170) Google Scholar, 7Sørensen H. Brand C.L. Neschen S. Holst J.J. Fosgerau K. Nishimura E. Shulman G.I. Immunoneutralization of endogenous glucagon reduces hepatic glucose output and improves long-term glycemic control in diabetic ob/ob mice.Diabetes. 2006; 55: 2843-2848Crossref PubMed Scopus (65) Google Scholar). Genetic interventions using complete Gcgr knock-out mice also lowered fasting and fed glucose levels with increased GLP-1 and glucagon levels (8Gelling R.W. Du X.Q. Dichmann D.S. Romer J. Huang H. Cui L. Obici S. Tang B. Holst J.J. Fledelius C. et al.Lower blood glucose, hyperglucagonemia, and pancreatic alpha cell hyperplasia in glucagon receptor knockout mice.Proc. Natl. Acad. Sci. USA. 2003; 100: 1438-1443Crossref PubMed Scopus (424) Google Scholar, 9Parker J.C. Andrews K.M. Allen M.R. Stock J.L. McNeish J.D. Glycemic control in mice with targeted disruption of the glucagon receptor gene.Biochem. Biophys. Res. Commun. 2002; 290: 839-843Crossref PubMed Scopus (130) Google Scholar, 10Conarello S.L. Jiang G. Mu J. Li Z. Woods J. Zycband E. Ronan J. Liu F. Roy R.S. Zhu L. et al.Glucagon receptor knockout mice are resistant to diet-induced obesity and streptozotocin-mediated beta cell loss and hyperglycaemia.Diabetologia. 2007; 50: 142-150Crossref PubMed Scopus (166) Google Scholar). More importantly, intervention with glucagon receptor antagonists revealed an impressive circulating plasma glucose-lowering effect in humans (11Kelly R.P. Garhyan P. Abu-Raddad E.J. Fu H. Lim C. Prince M.J. Pinaire J.A. Loh M. Deeg M.A. Short-term treatment with glucagon receptor antagonist LY2409021 effectively reduces fasting blood glucose (FBG) and HbA1c in patients with type 2 diabetes mellitus (T2DM) [abstract].Diabetes. 2011; 60: A84Google Scholar, 12Engel S.S. Xu L. Andryuk P.J. Davies M.J. Amatruda J. Kaufman K. Goldstein B.J. Efficacy and tolerability of MK-0893, a glucagon receptor antagonist (GRA), in patients with type 2 diabetes (T2DM) [abstract].Diabetes. 2011; : A85Google Scholar). However, concerns over the association between glucagon receptor signaling inhibition and dyslipidemia, specifically, increased LDL-C levels from Gcgr knock-out mice and clinical data using a glucagon receptor antagonist, have been raised (8Gelling R.W. Du X.Q. Dichmann D.S. Romer J. Huang H. Cui L. Obici S. Tang B. Holst J.J. Fledelius C. et al.Lower blood glucose, hyperglucagonemia, and pancreatic alpha cell hyperplasia in glucagon receptor knockout mice.Proc. Natl. Acad. Sci. USA. 2003; 100: 1438-1443Crossref PubMed Scopus (424) Google Scholar, 12Engel S.S. Xu L. Andryuk P.J. Davies M.J. Amatruda J. Kaufman K. Goldstein B.J. Efficacy and tolerability of MK-0893, a glucagon receptor antagonist (GRA), in patients with type 2 diabetes (T2DM) [abstract].Diabetes. 2011; : A85Google Scholar). Although most studies of glucagon receptor signaling inhibition showed robust glucose lowering, the effects on lipids and the mechanisms linking hepatic glucagon action to LDL-C levels have not been elucidated. The dyslipidemia associated with type 2 diabetes typically involves increased triglycerides (TGs), reduced HDL-C levels, and increased cardiovascular risk (13Krauss R.M. Lipids and lipoproteins in patients with type 2 diabetes.Diabetes Care. 2004; 27: 1496-1504Crossref PubMed Scopus (491) Google Scholar). Cardiovascular risk is further increased when type 2 diabetes is complicated by elevated LDL-C levels. Thus, it is important to evaluate the impact of hepatic glucagon action inhibition on lipid metabolism, especially hepatic lipid synthesis, TG secretion, and levels of LDL-C and HDL-C. The objective of the present study was to explore the effect of hepatic glucagon receptor ablation on lipid metabolism in a db/db diabetic mouse model. Male, 8 week-old db/db mice were purchased from The Jackson Laboratory (Bar Harbor, ME) and fed a regular chow diet (Diet 7012; Harlan Teklad) throughout the study. Following a 2 week stabilizing period, 10 week-old mice were used for small interfering RNA (siRNA) injection. siRNA was packaged in lipid nanoparticles, as previously described (14Tadin-Strapps M. Peterson L.B. Cumiskey A.M. Rosa R.L. Mendoza V.H. Castro-Perez J. Puig O. Zhang L. Strapps W.R. Yendluri S. et al.siRNA-induced liver ApoB knockdown lowers serum LDL-cholesterol in a mouse model with human-like serum lipids.J. Lipid Res. 2011; 52: 1084-1097Abstract Full Text Full Text PDF PubMed Scopus (56) Google Scholar). Chemically modified siRNAs were synthesized and characterized, as previously described (14Tadin-Strapps M. Peterson L.B. Cumiskey A.M. Rosa R.L. Mendoza V.H. Castro-Perez J. Puig O. Zhang L. Strapps W.R. Yendluri S. et al.siRNA-induced liver ApoB knockdown lowers serum LDL-cholesterol in a mouse model with human-like serum lipids.J. Lipid Res. 2011; 52: 1084-1097Abstract Full Text Full Text PDF PubMed Scopus (56) Google Scholar). 5ʹ-UGGUCAAGUGUCUGUUUGA-3ʹand 5ʹ-GGACTTCTCTCAATTTTCT-3ʹ were siRNA target sequences for Gcgr and a nontargeting control siRNA, respectively. The encapsulated siRNAs were injected via tail vein in a 3 mg/kg dose on days 0 and 6. Animals were euthanized at day 11, and blood and liver samples were collected immediately following euthanasia. Animal procedures were practiced in conformity with Public Health Service policy and the guidelines of the Institutional Animal Care and Use Committee of Merck. Ambient (nonfasted) plasma glucose levels were measured at 9:00 AM from tail bleeds with a glucometer (One Touch Ultra; LifeScan, Inc., Milpitas, CA) at day 4 and day 11 after siRNA injection. At day 11, mice were fasted for 5 h, and blood samples were collected. Plasma was separated by centrifugation and stored at -80°C until analysis. Total plasma cholesterol and HDL-C were measured using commercial kits (Wako Chemicals; Richmond, VA) according to the manufacturers’ protocol. Plasma insulin and TG levels were measured using an ALPCO ELISA kit (ALPCO Diagnostics; Salem, NH) and the Infinity Triglycerides kit (Thermo Fisher Scientific; Waltham, MA), respectively, according to the manufacturers’ instructions. Glucagon was measured using commercial ELISA kits (Linco Research Immunoassay; St. Charles, MO). Nonesterified fatty acid (NEFA) was measured using commercially available enzyme-coupled spectrophotometric assays (Wako Chemicals, Inc.), and β hydroxybutylate (bHB) was measured using the Liquid Enzymatic Reagent Kit (Stanbio Laboratory; Boerne, TX). Plasma apoB and apoA-I levels were measured by LC/MS assay, and protein convertase subtilisin/kexin type 9 (PCSK9) was measured using murine-specific ELISA, as previously described (14Tadin-Strapps M. Peterson L.B. Cumiskey A.M. Rosa R.L. Mendoza V.H. Castro-Perez J. Puig O. Zhang L. Strapps W.R. Yendluri S. et al.siRNA-induced liver ApoB knockdown lowers serum LDL-cholesterol in a mouse model with human-like serum lipids.J. Lipid Res. 2011; 52: 1084-1097Abstract Full Text Full Text PDF PubMed Scopus (56) Google Scholar, 15Chen Z. Wang S.P. Krsmanovic M.L. Castro-Perez J. Gagen K. Mendoza V. Rosa R. Shah V. He T. Stout S.J. et al.Small molecule activation of lecithin cholesterol acyltransferase modulates lipoprotein metabolism in mice and hamsters.Metabolism. 2012; 61: 470-481Abstract Full Text Full Text PDF PubMed Scopus (37) Google Scholar). All assays were performed following the recommended procedures for instrument operation, calibration, quality control, and assay guidelines. Hepatic TG and cholesterol content were measured as previously described (16Han S. Liang C.P. Westerterp M. Senokuchi T. Welch C.L. Wang Q. Matsumoto M. Accili D. Tall A.R. Hepatic insulin signaling regulates VLDL secretion and atherogenesis in mice.J. Clin. Invest. 2009; 119: 1029-1041PubMed Google Scholar). To examine expression of proteins, liver samples were collected and cell lysates were prepared as described previously (16Han S. Liang C.P. Westerterp M. Senokuchi T. Welch C.L. Wang Q. Matsumoto M. Accili D. Tall A.R. Hepatic insulin signaling regulates VLDL secretion and atherogenesis in mice.J. Clin. Invest. 2009; 119: 1029-1041PubMed Google Scholar). Western blot analysis was carried out as described earlier (16Han S. Liang C.P. Westerterp M. Senokuchi T. Welch C.L. Wang Q. Matsumoto M. Accili D. Tall A.R. Hepatic insulin signaling regulates VLDL secretion and atherogenesis in mice.J. Clin. Invest. 2009; 119: 1029-1041PubMed Google Scholar) using anti-Ldlr antibody (Abcam, PLC; Waltham, MA) and anti-α tubulin (Abcam, PLC). The major lipoproteins (VLDL-C; d < 1.006 g/ml), LDL-C (d = 1.006–1.063 g/ml), and HDL-C (d = 1.063–1.21 g/ml) were isolated by sequential density ultracentrifugation of plasma using a TLA-100 rotor (Beckman Coulter, Inc.; Brea, CA), following procedures described previously (16Han S. Liang C.P. Westerterp M. Senokuchi T. Welch C.L. Wang Q. Matsumoto M. Accili D. Tall A.R. Hepatic insulin signaling regulates VLDL secretion and atherogenesis in mice.J. Clin. Invest. 2009; 119: 1029-1041PubMed Google Scholar). Sodium bromide (NaBr) (Sigma-Aldrich, St. Louis, MO) was used to prepare the density solution. ApoB-containing lipoproteins were run on SDS-PAGE gels and visualized by 0.05% Coomassie blue staining (Sigma-Aldrich). P407 (Pluronic F-127; Invitrogen, Grand Island, NY) was used in mice to measure TG production rate in plasma. Mice were fasted overnight and injected with P407 (10 ml/kg body weight). Blood samples were collected at 0, 1, 2, 4, and 6 h after injection, and TG levels were quantified, as described above. Lipoproteins were fractionated by fast protein liquid chromatography (FPLC) gel filtration using a Superose-6 size exclusion column (GE Healthcare LifeSciences, Inc.; Piscataway, NJ) attached to a Dionex HPLC system (Thermo Fisher Scientific, Inc.). The column effluent was mixed with a commercially available enzymatic reagent for cholesterol (Wako Chemicals), and levels were continuously measured using a photodiode array detector at 600 nm absorbance. The first, second, and third peaks were attributed to VLDL, LDL-C, and HDL-C, respectively, and the area under each peak was calculated using Chromeleon software, as previously described (17Han S. Flattery A.M. McLaren D. Raubertas R. Lee S.H. Mendoza V. Rosa R. Geoghagen N. Castro-Perez J.M. Roddy T.P. et al.Comparison of lipoprotein separation and lipid analysis methodologies for human and cynomolgus monkey plasma samples.J. Cardiovasc. Transl. Res. 2012; 5: 75-83Crossref PubMed Scopus (13) Google Scholar). Liver samples were homogenized, and total RNA was isolated using RNA Easy (Qiagen, Inc., Valencia, CA), according to the manufacturer's instructions. Two micrograms total RNA from each sample was reverse transcribed with a cDNA kit (Life Technologies Corp., Carlsbad, CA), and mRNA expression for the genes of interest was measured by RT-PCR, with SYBR Green PCR core reagents and primers (Qiagen, Inc.), as previously described (18Jensen K.K. Previs S.F. Zhu L. Herath K. Wang S.P. Bhat G. Hu G. Miller P.L. McLaren D.G. Shin M.K. et al.Demonstration of diet-induced decoupling of fatty acid and cholesterol synthesis by combining gene expression array and 2H2O quantification.Am. J. Physiol. Endocrinol. Metab. 2012; 302: E209-E217Crossref PubMed Scopus (16) Google Scholar). The relative amounts of specific target amplicons for each primer set were estimated by a cycle threshold (Ct) value and were normalized to the copy number of housekeeping genes (18Jensen K.K. Previs S.F. Zhu L. Herath K. Wang S.P. Bhat G. Hu G. Miller P.L. McLaren D.G. Shin M.K. et al.Demonstration of diet-induced decoupling of fatty acid and cholesterol synthesis by combining gene expression array and 2H2O quantification.Am. J. Physiol. Endocrinol. Metab. 2012; 302: E209-E217Crossref PubMed Scopus (16) Google Scholar). The P values were determined by two-tailed equal variance Student's t-test, comparing the ΔCt values of the si-Control and si-GCGR groups. At day 11 after siRNA injection, 2H2O (Sigma-Aldrich) was injected at 20 ml/kg body weight into animals that had been fasted 4 h. Plasma samples were collected after 4 h of tracer incorporation, and stored at -80°C until analysis. Total plasma (35 µl) was spiked with a known amount of heptadecanoic acid (C17:0, internal standard) and then saponified in 1 N potassium hydroxide (KOH) in 80% ethanol (heated at 65°C for 60 minutes). Samples were acidified (25 µl 6 N hydrochloric acid (HCl), and the lipids were then extracted with chlor09 oform. Following evaporation of the solvent, the residue was first reacted with trimethylsilyldiazomethane to form FA methyl esters, evaporated to dryness, and then reacted with pyridine-acetic anhydride (1:1, v/v) at 65°C for 30 min to generate cholesterol acetate. The reagents were evaporated to dryness. The 2H labeling of the derivatized lipids was determined using an Agilent 5973N-MSD equipped with an Agilent 6890 GC system (Agilent Technologies; Santa Clara, CA), a DB5-MS capillary column (30 m x 0.25 mm x 0.25 µm). The mass spectrometer was operated in the electron impact mode, using selective ion monitoring of m/z 270 and 271 for palmitate, 284 and 285 for C17:0 (internal standard), and 368 and 369 for cholesterol; data were collected using selected ion monitoring at a dwell time of 10 ms per ion. To quantify the contribution of lipid synthesis, a precursor product labeling ratio was assumed and the general equation was used: %newlymadematerial=productlabeling/(precursor labeling×n)×100Eq. 1 for which product labeling = palmitate or cholesterol, precursor labeling = body water, and n= the number of exchangeable hydrogens (assumed to equal 22 and 25 for palmitate and cholesterol, respectively) (19Lee W.N. Bassilian S. Ajie H.O. Schoeller D.A. Edmond J. Bergner E.A. Byerley L.O. In vivo measurement of fatty acids and cholesterol synthesis using D2O and mass isotopomer analysis.Am. J. Physiol. 1994; 266: E699-E708Crossref PubMed Google Scholar, 20Diraison F. Pachiaudi C. Beylot M. In vivo measurement of plasma cholesterol and fatty acid synthesis with deuterated water: determination of the average number of deuterium atoms incorporated.Metabolism. 1996; 45: 817-821Abstract Full Text PDF PubMed Scopus (76) Google Scholar). Values are expressed as means ± SEM. The statistical significance of the differences was determined by Student's t-test, and a P value <0.05 was considered significant. Eleven days after siRNA injection, a reduction in hepatic Gcgr mRNA expression (61%) in si-GCGR mice was observed (Fig. 1A). There was no difference in cumulative body weight in the si-GCGR group compared with the control group throughout the study (Fig. 1B). Compared with si-Control mice, both ambient and fasting glucose levels in si-GCGR-treated mice were reduced at day 4, and the reduction was sustained to day 11 after treatment (Fig. 1C, D). Although plasma glucagon levels were elevated in the si-GCGRsi-GCGR-treated mice, plasma insulin levels were similar in the two groups (Fig. 1E, F). Lipoprotein analysis showed a 2-fold increase of LDL-C levels in si-GCGR-treated mice compared with those in the si-Control group, with no significant difference in VLDL and HDL-C levels (Fig. 2A). In addition, there were no differences in hepatic LDL receptor expression, plasma PCSK9 levels, or lipoprotein lipase activity between these two groups (Fig. 2B, C; see supplementary Fig. IA). The use of ultracentrifugation to isolate lipoprotein fractions revealed a slight increase in apoB-100 content in LDL fractions, with a tendency toward increased total plasma apoB levels in si-GCGR mice (Fig. 2D, E). FPLC separation confirmed an increase of LDL-C fraction in si-GCGR mice (Fig. 2F). There were increased levels of TGs and cholesterol in the liver samples from si-GCGR mice (Fig. 3A). This increase may have potentially resulted from increased expression of hepatic lipogenic genes. There was no differential expression of sterol-regulatory element-binding protein isoform-1c (Srebf1) or SREBP-2 (Srebf2) mRNA in fed liver samples from si-GCGR mice compared with controls (Fig. 3B). However, we observed a profound increase in the expression of genes in SREBP pathways, such as FA synthase (Fasn), acetyl-CoA carboxylase A and B (Acaca, Acacb), stearoyl-CoA desaturase (Scd1), elongation of very long-chain fatty acids protein (Elovl5, Elovl6), long-chain-fatty acid-CoA ligase (Acsl3, Acsl5), Acyl-CoA synthetase short-chain family member 2 (Acss2), ATP citrate lyase (Acly), acetoacetyl-CoA synthetase (Aacs), mevalonate decarboxylase (Mvd), and farnesyl diphosphate synthetase (Fdps) (Fig. 3B). A tendency of increased expression was shown by 3-hydroxy-3-methylglutaryl-CoA reductase (Hmgcr), whereas MLX interactor (Chrebp) mRNA expression was unchanged (Fig. 3B). Microsomal triglyceride transfer protein (Mttp) showed a moderate increase in expression, whereas other potential candidate molecules involved in the regulation of apoB-containing lipoprotein levels, including apoB, Lpl, PCSK9, or Ldlr mRNA expression, were unchanged (Fig. 3B). As expected with inhibition of glucagon signaling, the expression of glucokinase (Gck) and pyruvate kinase (Pklr) was increased, and the expression of phosphoenolpyruvate carboxykinase (Pepck) was decreased in the hepatic Gcgr knockdown mice group (Fig. 3B). Upregulation of lipogenic and glycogen biosynthetic genes and reduction of gluconeogenic gene expression were observed with hepatic Gcgr knockdown. These findings suggest that reduced levels of hepatic glucagon receptor in db/db mice produce an upregulation of lipogenic genes, which may eventually lead to increased hepatic lipid contents. Stable isotope tracer studies were performed to determine whether increased expression of hepatic lipogenic genes translated into increased lipid synthesis in si-GCGR mice. To quantify the rate of de novo lipogenesis, both groups of mice were injected with 2H2O tracer, and the 2H labeling of cholesterol and palmitate was quantified using GC/MS. A significant increase in the synthesis of cholesterol (>2-fold) and palmitate (>5-fold) was observed in si-GCGR-treated groups relative to controls (Fig. 4A, B). Presumably, changes in the production of these plasma lipids reflect hepatic metabolism, because the liver is a major source of newly made circulating lipids. To determine whether these changes lead to altered hepatic lipoprotein secretion, the lipase inhibitor P407 was administered by injection to both groups of mice. P407 blocks the clearance of apoB-containing lipoproteins from the circulation; thus, the rate of accumulation of lipoprotein reflects the secretion rate in plasma. The results showed an increase in hepatic secretion of TGs in si-GCGR mice as well as increased basal plasma TG levels (Fig. 4C, D). Compared with control groups, there was no difference in plasma levels of NEFA, bHB, alanine transaminase, and aspartate aminotransferase in the si-GCGR group (Fig. 4E, F; see supplementary Fig. IB). Targeting glucagon action to treat type 2 diabetes has been of great interest. This study demonstrated a strong and sustained effect on glucose lowering in siRNA-mediated hepatic Gcgr knockdown in db/db mice. Previous studies have shown that inhibiting glucagon action improves glycemic control in animals and humans (9Parker J.C. Andrews K.M. Allen M.R. Stock J.L. McNeish J.D. Glycemic control in mice with targeted disruption of the glucagon receptor gene.Biochem. Biophys. Res. Commun. 2002; 290: 839-843Crossref PubMed Scopus (130) Google Scholar, 11Kelly R.P. Garhyan P. Abu-Raddad E.J. Fu H. Lim C. Prince M.J. Pinaire J.A. Loh M. Deeg M.A. Short-term treatment with glucagon receptor antagonist LY2409021 effectively reduces fasting blood glucose (FBG) and HbA1c in patients with type 2 diabetes mellitus (T2DM) [abstract].Diabetes. 2011; 60: A84Google Scholar, 12Engel S.S. Xu L. Andryuk P.J. Davies M.J. Amatruda J. Kaufman K. Goldstein B.J. Efficacy and tolerability of MK-0893, a glucagon receptor antagonist (GRA), in patients with type 2 diabetes (T2DM) [abstract].Diabetes. 2011; : A85Google Scholar, 21Mu J. Jiang G. Brady E. Dallas-Yang Q. Liu F. Woods J. Zycband E. Wright M. Li Z. Lu K. et al.Chronic treatment with a glucagon receptor antagonist lowers glucose and moderately raises circulating glucagon and glucagon-like peptide 1 without severe alpha cell hypertrophy in diet-induced obese mice.Diabetologia. 2011; 54: 2381-2391Crossref PubMed Scopus (58) Google Scholar). Consistent with those observations, the present results indicate that blocking GCGR activation can improve glucose control in a diabetic mouse model. Although such therapies have consistently demonstrated improvement of glucose in different mouse models and even human clinical trials, questions regarding the potential effects of blocking glucagon action on lipid metabolism have been raised. Interestingly, several other studies have also illustrated the potential hypolipidemic actions of glucagon, specifically, with respect to reduced plasma TG, VLDL secretion, hepatic TG contents, cholesterol levels, and increased FA oxidation (22Eaton R.P. Hypolipemic action of glucagon in experimental endogenous lipemia in the rat.J. Lipid Res. 1973; 14: 312-318Abstract Full Text PDF PubMed Google Scholar, 23Longuet C. Sinclair E.M. Maida A. Baggio L.L. Maziarz M. Charron M.J. Drucker D.J. The glucagon receptor is required for the adaptive metabolic response to fasting.Cell Metab. 2008; 8: 359-371Abstract Full Text Full Text PDF PubMed Scopus (177) Google Scholar, 24Xiao C. Pavlic M. Szeto L. Patterson B.W. Lewis G.F. Effects of acute hyperglucagonemia on hepatic and intestinal lipoprotein production and clearance in healthy humans.Diabetes. 2011; 60: 383-390Crossref PubMed Scopus (44) Google Scholar, 25Aubry F. Marcel Y.L. Davignon J. Effects of glucagon on plasma lipids in different types of primary hyperlipoproteinemia.Metabolism. 1974; 23: 225-238Abstract Full Text PDF PubMed Scopus (27) Google Scholar). These findings underscore the importance of understanding the potential implications of downregulating glucagon signaling on lipid metabolism. Previously published studies examining GCGR inhibition revealed somewhat inconsistent results with respect to lipid effects, insofar as not all Gcgr-/- mice or GCGR ASO-treated mice exhibited dyslipidemic phenotypes (5Sloop K.W. Cao J.X. Siesky A.M. Zhang H.Y. Bodenmiller D.M. Cox A.L. Jacobs S.J. Moyers J.S. Owens R.A. Showalter A.D. et al.Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors.J. Clin. Invest. 2004; 113: 1571-1581Crossref PubMed Scopus (189) Google Scholar, 6Liang Y. Osborne M.C. Monia B.P. Bhanot S. Gaarde W.A. Reed C. She P. Jetton T.L. Demarest K.T. Reduction in glucagon receptor expression by an antisense oligonucleotide ameliorates diabetic syndrome in db/db mice.Diabetes. 2004; 53: 410-417Crossref PubMed Scopus (170) Google Scholar, 8Gelling R.W. Du X.Q. Dichmann D.S. Romer J. Huang H. Cui L. Obici S. Tang B. Holst J.J. Fledelius C. et al.Lower blood glucose, hyperglucagonemia, and pancreatic alpha cell hyperplasia in glucagon receptor knockout mice.Proc. Natl. Acad. Sci. USA. 2003; 100: 1438-1443Crossref PubMed Scopus (424) Google Scholar, 9Parker J.C. Andrews K.M. Allen M.R. Stock J.L. McNeish J.D. Glycemic control in mice with targeted disruption of the glucagon receptor gene.Biochem. Biophys. Res. Commun. 2002; 290: 839-843Crossref PubMed Scopus (130) Google Scholar, 23Longuet C. Sinclair E.M. Maida A. Baggio L.L. Maziarz M. Charron M.J. Drucker D.J. The glucagon receptor is required for the adaptive metabolic response to fasting.Cell Metab. 2008; 8: 359-371Abstract Full Text Full Text PDF PubMed Scopus (177) Google Scholar). In some studies, Gcgr-/- mice showed increased plasma LDL or total cholesterol levels, but no increased (or even reduced) plasma TG levels (8Gelling R.W. Du X.Q. Dichmann D.S. Romer J. Huang H. Cui L. Obici S. Tang B. Holst J.J. Fledelius C. et al.Lower blood glucose, hyperglucagonemia, and pancreatic alpha cell hyperplasia in glucagon receptor knockout mice.Proc. Natl. Acad. Sci. USA. 2003; 100: 1438-1443Crossref PubMed Scopus (424) Google Scholar, 9Parker J.C. Andrews K.M. Allen M.R. Stock J.L. McNeish J.D. Glycemic control in mice with targeted disruption of the glucagon receptor gene.Biochem. Biophys. Res. Commun. 2002; 290: 839-843Crossref PubMed Scopus (130) Google Scholar). In another study, Gcgr-/- mice showed increased TG secretion and increased plasma TG levels after a 16 h fast (23Longuet C. Sinclair E.M. Maida A. Baggio L.L. Maziarz M. Charron M.J. Drucker D.J. The glucagon receptor is required for the adaptive metabolic response to fasting.Cell Metab. 2008; 8: 359-371Abstract Full Text Full Text PDF PubMed Scopus (177) Google Scholar). GCGR ASO-treated db/db mice showed reduced plasma TG levels and increased hepatic TG contents (5Sloop K.W. Cao J.X. Siesky A.M. Zhang H.Y. Bodenmiller D.M. Cox A.L. Jacobs S.J. Moyers J.S. Owens R.A. Showalter A.D. et al.Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors.J. Clin. Invest. 2004; 113: 1571-1581Crossref PubMed Scopus (189) Google Scholar, 6Liang Y. Osborne M.C. Monia B.P. Bhanot S. Gaarde W.A. Reed C. She P. Jetton T.L. Demarest K.T. Reduction in glucagon receptor expression by an antisense oligonucleotide ameliorates diabetic syndrome in db/db mice.Diabetes. 2004; 53: 410-417Crossref PubMed Scopus (170) Google Scholar). In the current study, inhibition of GCGR by si-RNA demonstrated effects on both glucose and lipid metabolism in the db/db mouse model. The si-GCGR db/db mouse showed robust glucose lowering and increased LDL-C levels. Si-GCGR mice showed increased hepatic lipid contents, lipogenic gene expression, and TG production. All of these aggravated dyslipidemic characteristics are associated with an upregulation of de novo lipogenesis. We did not observe any increase in plasma NEFA concentrations to suggest increased FA flux to liver, nor a reduction in β-hydroxybutyrate levels and/or reduction in the expression of FA oxidation genes in si-GCGR mice (Fig. 4E, F; data not shown). Hepatic LDLR protein and plasma PCSK9 levels were also unchanged; therefore, the increasing LDL-C is probably less due to the reduction in LDL fractional catabolism. On the basis of our results, we propose that the elevated rate of lipogenesis is a major driving force for the observed increases in LDL-C levels and increased TG production in si-GCGR db/db mice. Interestingly, siRNA-mediated knock down of fructose-1,6-bisphosphatase 1, which converts fructose 1,6 biphosphate to fructose 6-phosphate in gluconeogenesis, also reduced plasma glucose levels, increased LDL-C levels, and upregulated expression of hepatic lipogenic gene expression in the db/db mouse model (see supplementary Fig. II; data not shown). We also tested the effect of knockdown glucagon receptor in a mouse model without impairment of leptin signaling, CETP transgenic LDLR+/- mouse, using siRNA targeting Gcgr. The si-GCGR-treated mice showed ~20% reduction in plasma glucose and ~24% induction of LDL-C levels in the CETP-transgenic LDLR+/- mouse model (see supplementary Fig. III). The inhibition of hepatic gluconeogenesis and possible increase in glycolysis in si-GCGR mice could lead to build-up of acetyl-CoA, which can be used as carbon substrate for lipid synthesis. The newly synthesized hepatic lipid can be either stored or secreted as VLDL. Certainly, we observed increased hepatic lipid contents as well as increased TG production. Another explanation could be that knocking down GCGR sensitized the liver to insulin-mediated lipogenesis. It is well documented that insulin upregulates FA biosynthesis and glycolysis genes. One study showed inhibitory effects of glucagon on hepatic lipogenesis by antagonizing the signaling pathway mediated by insulin (26Xiong Y. Collins Q.F. An J. Lupo Jr, E. Liu H.Y. Liu D. Robidoux J. Liu Z. Cao W. p38 mitogen-activated protein kinase plays an inhibitory role in hepatic lipogenesis.J. Biol. Chem. 2007; 282: 4975-4982Abstract Full Text Full Text PDF PubMed Scopus (79) Google Scholar). A recent study showed a global upregulation of lipid biosynthesis and glycolysis genes in Gcgr-/- mice liver at both mRNA and protein levels (27Yang J. MacDougall M.L. McDowell M.T. Xi L. Wei R. Zavadoski W.J. Molloy M.P. Baker J.D. Kuhn M. Cabrera O. et al.Polyomic profiling reveals significant hepatic metabolic alterations in glucagon-receptor (GCGR) knockout mice: implications on anti-glucagon therapies for diabetes.BMC Genomics. 2011; 12: 281Crossref PubMed Google Scholar). Importantly, Gcgr knockout or Gcgr monoclonal antibody-treated preclinical animal models showed elevated plasma cholesterol and LDL cholesterol (8Gelling R.W. Du X.Q. Dichmann D.S. Romer J. Huang H. Cui L. Obici S. Tang B. Holst J.J. Fledelius C. et al.Lower blood glucose, hyperglucagonemia, and pancreatic alpha cell hyperplasia in glucagon receptor knockout mice.Proc. Natl. Acad. Sci. USA. 2003; 100: 1438-1443Crossref PubMed Scopus (424) Google Scholar, 28Gu W. Yan H. Winters K.A. Komorowski R. Vonderfecht S. Atangan L. Sivits G. Hill D. Yang J. Bi V. et al.Long-term inhibition of the glucagon receptor with a monoclonal antibody in mice causes sustained improvement in glycemic control, with reversible alpha-cell hyperplasia and hyperglucagonemia.J. Pharmacol. Exp. Ther. 2009; 331: 871-881Crossref PubMed Scopus (85) Google Scholar), which might be caused by increased hepatic cholesterol synthesis. Indeed, our stable isotope tracer studies demonstrated that cholesterol synthesis (2H labeling of cholesterol) was significantly increased in si-GCGR-treated mice. It is interesting to note that we did not observe robust change of gene expressions involved in cholesterol synthesis, which is somewhat inconsistent with the report that multiple genes of cholesterol biosynthesis were elevated in Gcgr-/- mice (27Yang J. MacDougall M.L. McDowell M.T. Xi L. Wei R. Zavadoski W.J. Molloy M.P. Baker J.D. Kuhn M. Cabrera O. et al.Polyomic profiling reveals significant hepatic metabolic alterations in glucagon-receptor (GCGR) knockout mice: implications on anti-glucagon therapies for diabetes.BMC Genomics. 2011; 12: 281Crossref PubMed Google Scholar). This discrepancy might be due to differences in the genetic background, the dysmetabolic status of mice, and the degree of GCGR deficiency. The implications of these findings could be that glucagon/GCGR signaling not only plays a role in glucose metabolism but also protects against excessive hepatic lipid production. Given that increased atherosclerosis is a major cause of morbidity and mortality in type 2 diabetes and metabolic syndrome (29Nigro J. Osman N. Dart A.M. Little P.J. Insulin resistance and atherosclerosis.Endocr. Rev. 2006; 27: 242-259Crossref PubMed Scopus (260) Google Scholar), it is important to carefully evaluate the potential association of increased LDL cholesterol levels when GCGR is antagonized. The current study demonstrated the potential association between hepatic glucagon signaling and regulation of lipogenesis and plasma LDL in the db/db mouse model. Although there may be concerns with respect to directly applying results from a mouse model to human lipid metabolism, the hepatic Gcgr knockdown in db/db mice is a useful model by which to study the interaction of hepatic glucagon signaling and lipid metabolism. Whether the glucose and lipid effects can be decoupled at the glucagon receptor level will be of great interest to the field. Understanding the glucagon/GCGR mechanisms that control lipid metabolism will provide important insights to guide the design of the next generation of GCGR antagonists for the treatment of type 2 diabetes. The authors thank Christine McCrary Sisk and Kathleen Newcomb of Merck Sharp & Dohme Corp., for their editorial assistance in the preparation of this manuscript and Xun Shen of Merck Sharp & Dohme Corp. for generating the Western blot analysis data set. Download .zip (.17 MB) Help with zip files antisense oligonucleotide β hydroxybutylate fast protein liquid chromatography nonesterified fatty acid small interfering RNA triglyceride" @default.
• W2059663906 created "2016-06-24" @default.
• W2059663906 creator A5001500351 @default.
• W2059663906 creator A5011850541 @default.
• W2059663906 creator A5012677271 @default.
• W2059663906 creator A5017593302 @default.
• W2059663906 creator A5024027579 @default.
• W2059663906 creator A5038471465 @default.
• W2059663906 creator A5042357483 @default.
• W2059663906 creator A5046839995 @default.
• W2059663906 creator A5069133442 @default.
• W2059663906 creator A5072589586 @default.
• W2059663906 creator A5072902528 @default.
• W2059663906 creator A5073022316 @default.
• W2059663906 creator A5079675631 @default.
• W2059663906 creator A5080562890 @default.
• W2059663906 creator A5086511717 @default.
• W2059663906 date "2013-10-01" @default.
• W2059663906 modified "2023-10-06" @default.
• W2059663906 title "Effects of small interfering RNA-mediated hepatic glucagon receptor inhibition on lipid metabolism in db/db mice" @default.
• W2059663906 cites W1963554091 @default.
• W2059663906 cites W1983069289 @default.
• W2059663906 cites W1984152453 @default.
• W2059663906 cites W1988784323 @default.
• W2059663906 cites W2003946536 @default.
• W2059663906 cites W2019703657 @default.
• W2059663906 cites W2036141586 @default.
• W2059663906 cites W2046912474 @default.
• W2059663906 cites W2070284998 @default.
• W2059663906 cites W2080687603 @default.
• W2059663906 cites W2085330452 @default.
• W2059663906 cites W2087619497 @default.
• W2059663906 cites W2095995901 @default.
• W2059663906 cites W2105362864 @default.
• W2059663906 cites W2113126709 @default.
• W2059663906 cites W2116862105 @default.
• W2059663906 cites W2127167047 @default.
• W2059663906 cites W2147903228 @default.
• W2059663906 cites W2149501280 @default.
• W2059663906 cites W2155214511 @default.
• W2059663906 cites W2156888164 @default.
• W2059663906 cites W2161720416 @default.
• W2059663906 cites W2168726045 @default.
• W2059663906 cites W2171147666 @default.
• W2059663906 cites W2171474087 @default.
• W2059663906 doi "https://doi.org/10.1194/jlr.m035592" @default.
• W2059663906 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3770075" @default.
• W2059663906 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23828778" @default.
• W2059663906 hasPublicationYear "2013" @default.
• W2059663906 type Work @default.
• W2059663906 sameAs 2059663906 @default.
• W2059663906 citedByCount "27" @default.
• W2059663906 countsByYear W20596639062014 @default.
• W2059663906 countsByYear W20596639062015 @default.
• W2059663906 countsByYear W20596639062016 @default.
• W2059663906 countsByYear W20596639062017 @default.
• W2059663906 countsByYear W20596639062018 @default.
• W2059663906 countsByYear W20596639062019 @default.
• W2059663906 countsByYear W20596639062021 @default.
• W2059663906 countsByYear W20596639062022 @default.
• W2059663906 countsByYear W20596639062023 @default.
• W2059663906 crossrefType "journal-article" @default.
• W2059663906 hasAuthorship W2059663906A5001500351 @default.
• W2059663906 hasAuthorship W2059663906A5011850541 @default.
• W2059663906 hasAuthorship W2059663906A5012677271 @default.
• W2059663906 hasAuthorship W2059663906A5017593302 @default.
• W2059663906 hasAuthorship W2059663906A5024027579 @default.
• W2059663906 hasAuthorship W2059663906A5038471465 @default.
• W2059663906 hasAuthorship W2059663906A5042357483 @default.
• W2059663906 hasAuthorship W2059663906A5046839995 @default.
• W2059663906 hasAuthorship W2059663906A5069133442 @default.
• W2059663906 hasAuthorship W2059663906A5072589586 @default.
• W2059663906 hasAuthorship W2059663906A5072902528 @default.
• W2059663906 hasAuthorship W2059663906A5073022316 @default.
• W2059663906 hasAuthorship W2059663906A5079675631 @default.
• W2059663906 hasAuthorship W2059663906A5080562890 @default.
• W2059663906 hasAuthorship W2059663906A5086511717 @default.
• W2059663906 hasBestOaLocation W20596639061 @default.
• W2059663906 hasConcept C104317684 @default.
• W2059663906 hasConcept C126322002 @default.
• W2059663906 hasConcept C134018914 @default.
• W2059663906 hasConcept C170493617 @default.
• W2059663906 hasConcept C185592680 @default.
• W2059663906 hasConcept C22615655 @default.
• W2059663906 hasConcept C2778563252 @default.
• W2059663906 hasConcept C2779306644 @default.
• W2059663906 hasConcept C4733338 @default.
• W2059663906 hasConcept C55493867 @default.
• W2059663906 hasConcept C62231903 @default.
• W2059663906 hasConcept C67705224 @default.
• W2059663906 hasConcept C71924100 @default.
• W2059663906 hasConcept C86803240 @default.
• W2059663906 hasConceptScore W2059663906C104317684 @default.
• W2059663906 hasConceptScore W2059663906C126322002 @default.
• W2059663906 hasConceptScore W2059663906C134018914 @default.
• W2059663906 hasConceptScore W2059663906C170493617 @default.
• W2059663906 hasConceptScore W2059663906C185592680 @default.
• W2059663906 hasConceptScore W2059663906C22615655 @default.

• next